We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

137 hedge funds and large institutions have $145M invested in Karyopharm Therapeutics in 2023 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 43 increasing their positions, 41 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more call options, than puts

Call options by funds: $613K | Put options by funds: $242K

36% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 22

6% more funds holding

Funds holding: 129 → 137 (+8)

5% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 41

0.38% less ownership

Funds ownership: 5.15% → 4.77% (-0.38%)

57% less capital invested

Capital invested by funds: $340M → $145M (-$195M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
137
Holders Change
+8
Holders Change %
+6.2%
% of All Funds
2.15%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
30
Increased
43
Reduced
41
Closed
22
Calls
$613K
Puts
$242K
Net Calls
+$371K
Net Calls Change
-$148K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.08M
2
ECM
ExodusPoint Capital Management
New York
+$6.84M
3
ACM
AIGH Capital Management
Maryland
+$5.09M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.39M
5
Millennium Management
Millennium Management
New York
+$3.27M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$22.9M
2
RCMNY
Rubric Capital Management (New York)
New York
-$10.1M
3
Bank of America
Bank of America
North Carolina
-$5.23M
4
Barclays
Barclays
United Kingdom
-$5M
5
N
Nuveen
North Carolina
-$3.78M
Name Holding Trade Value Shares
Change 		Change in
Stake
MLA
126
MB, Levis & Associates
Pennsylvania
$2.69K – – –
CUAMC
127
China Universal Asset Management Company
China
$2.67K -$86 -2 -2%
Group One Trading
128
Group One Trading
Illinois
$2.67K -$4.61K -107 -52%
HI
129
Harbour Investments
Wisconsin
$2.33K +$1.46K +34 +64%
TWC
130
TD Waterhouse Canada
Ontario, Canada
$1.9K – – –
Nisa Investment Advisors
131
Nisa Investment Advisors
Missouri
$1.43K -$172 -4 -7%
AF
132
Advisornet Financial
Minnesota
$1.25K – – –
Lazard Asset Management
133
Lazard Asset Management
New York
$1K – – –
AF
134
Allworth Financial
California
$895 – – –
KFS
135
Kelly Financial Services
Massachusetts
$448 – – –
HNB
136
Huntington National Bank
Ohio
$186 +$301 +7 New
FGAM
137
Financial Gravity Asset Management
Texas
$25 – – –
Rafferty Asset Management
138
Rafferty Asset Management
New York
– -$3.55M -60,887 Closed
AAA
139
Affinity Asset Advisors
New York
– -$1.79M -30,732 Closed
CANY
140
Caxton Associates (New York)
New York
– -$917K -15,708 Closed
State of Wisconsin Investment Board
141
State of Wisconsin Investment Board
Wisconsin
– -$768K -13,162 Closed
PA
142
Profund Advisors
Maryland
– -$652K -11,168 Closed
Tudor Investment Corp
143
Tudor Investment Corp
Connecticut
– -$588K -10,082 Closed
HWAM
144
Hennion & Walsh Asset Management
New Jersey
– -$543K -9,305 Closed
Los Angeles Capital Management
145
Los Angeles Capital Management
California
– -$442K -7,582 Closed
AG
146
Algert Global
California
– -$338K -5,788 Closed
FAM
147
Fred Alger Management
New York
– -$270K -4,628 Closed
Walleye Capital
148
Walleye Capital
New York
– -$221K -3,780 Closed
EFM
149
E Fund Management
China
– -$202K -3,457 Closed
Mirae Asset Global Investments
150
Mirae Asset Global Investments
South Korea
– -$145K -2,493 Closed
3 4 5
6
7

KPTI Hedge Fund Activity: Q2 2023 in Review

137 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2023, worth a combined $145M — down 57% from $340M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new KPTI positions and 22 closed out — a net gain of 8 holders — while 43 added to existing stakes and 41 trimmed.

The largest buyer was BlackRock, adding an estimated $7.08M. The largest seller was State Street, cutting an estimated $22.9M.

  • 137 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2023, up from 129 in Q1 2023.
  • Funds reported $145M of Karyopharm Therapeutics stock for Q2 2023, down 57% quarter-over-quarter.
  • 30 funds opened new Karyopharm Therapeutics positions in Q2 2023 and 22 closed out, a net change of +8 holders.
  • The largest Karyopharm Therapeutics buyer in Q2 2023 was BlackRock, an estimated $7.08M added.
  • The largest Karyopharm Therapeutics seller in Q2 2023 was State Street, an estimated $22.9M sold.

Based on aggregated 13F filings for Q2 2023.